Middle East & Africa Cancer Drugs Market Size and Forecast (2021 - 2031)

The Middle East and Africa (MEA) Cancer Drugs Market is projected to grow significantly, reaching an estimated US$ 8,816.2 million by 2031, up from US$ 4,415.8 million in 2024. This growth represents a compound annual growth rate (CAGR) of 10.4% from 2025 to 2031, driven by various factors including increasing cancer incidence, advancements in healthcare infrastructure, and the adoption of precision medicine.

Executive Summary and Market Analysis

The MEA region, particularly Turkey, the Gulf Cooperation Council (GCC) countries, and South Africa, leads in cancer drug sales. The rise in cancer cases is attributed to an aging population, urbanization, lifestyle changes, and improvements in healthcare systems, especially in the GCC and urban centers in South Africa. The trend towards precision medicine, which utilizes genetic profiling and biomarker-driven therapies, is becoming more prevalent in oncology practices across the region.

Government initiatives and regulatory reforms in GCC countries are facilitating quicker access to innovative cancer treatments. Additionally, the promotion of biosimilars and generics by government bodies aims to enhance the affordability of cancer medications. Strategic partnerships, such as Pharmalink's collaboration to commercialize sugemalimab in the MEA, are also strengthening the precision oncology pipeline.

Digital health innovations are playing a crucial role in improving access to cancer care, particularly in underserved areas of Sub-Saharan Africa. Platforms like Discovery Health in South Africa and Babylon Health in Kenya are pioneering telemedicine, AI triage, symptom tracking, and remote consultations, making cancer care more accessible.

Market Segmentation Analysis

The MEA Cancer Drugs Market is segmented by therapy types, indications, and distribution channels:

• By Therapy Types: The market includes Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, and Other Therapy Types. Targeted Therapy is the leading segment as of 2024.
• By Indications: The market is categorized into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications. The Other Indications segment was the largest in 2024.
• By Distribution Channel: The market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Stores, with Hospital Pharmacies dominating the market in 2024.

Market Outlook

The cancer drugs market is undergoing a significant transformation, largely due to the increasing preference for personalized medicine. This approach tailors treatments to the individual patient's molecular, genetic, and biomarker profiles. Technological advancements, particularly in next-generation sequencing (NGS), have reduced the costs and time required for tumor genome profiling, allowing for more precise targeting of therapies.

Companion diagnostics are becoming integral to clinical trial designs and routine oncology care, helping to identify actionable mutations and biomarkers. This shift has spurred innovation in therapeutic offerings, with tissue-agnostic drugs like pembrolizumab and entrectinib being approved based on shared genetic mutations rather than tumor types. Such advancements exemplify the move towards individualized cancer care.

Other personalized approaches, including functional drug sensitivity testing and patient-derived xenograft (PDX) models, are gaining traction, enabling clinicians to predict treatment responses more accurately. For instance, NIH researchers have developed a personalized cancer therapy that utilizes a patient’s immune cells to combat metastatic cancer. Both public and private sectors are increasing investments in biomarker-driven therapies and precision diagnostics, with major pharmaceutical companies forming collaborations to expedite the development of precision drug pipelines.

Artificial intelligence and machine learning are also enhancing drug design and patient stratification, leading to more efficient and effective personalized clinical trials. As a result, personalized medicine is expected to emerge as a significant growth trend in the cancer drug market during the forecast period.

Country Insights

The MEA Cancer Drugs Market is further segmented by country, including Turkey, GCC countries, South Africa, and the Rest of the Middle East and Africa. South Africa is anticipated to hold the largest market share in 2024.

Cancer remains a leading cause of death in South Africa, with prevalent types including breast, prostate, cervical, and lung cancer. According to GLOBOCAN data, approximately 108,168 new cancer cases were diagnosed in 2020, with 56,802 cancer-related deaths. The South African government is actively addressing the rising cancer burden through various initiatives aimed at improving access to cancer care and encouraging innovations in cancer therapies. National health policies are focused on enhancing cancer diagnosis and treatment, with the National Health Insurance (NHI) proposal aiming to provide comprehensive healthcare coverage, including cancer treatment, to all citizens.

Company Profiles

Key players in the MEA Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.